Lyra Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

Watertown, Massachusetts 8,134 followers

Clinical-stage biotechnology company developing innovative therapies for the localized treatment of CRS

About us

Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. Building on expertise in materials science, drug development and formulation, Lyra has developed proprietary technology that is designed to deliver medicines directly precisely and consistently to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, in-office procedure and intended to deliver up to six months of continuous mometasone furoate drug therapy to the sinonasal passages for the treatment of CRS.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Watertown, Massachusetts

Type

Public Company

Founded

2018

Specialties

Pharmaceuticals and Biotechnology

Locations

Employees at Lyra Therapeutics

Updates

Join now to see what you are missing

Join now

Similar pages

Browse jobs

Funding